Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00990782 · ClinicalTrials.gov registry record · NA
Capsule Endoscopy for Post-Ablation Esophageal Lesion Assessment
A NA study of Esophageal Lesion, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- NA
- Development phase
- 93
- Enrollment target
- 1
- Study location
NCT00990782: Completed NA study of Esophageal Lesion, sponsored by The Cleveland Clinic.
NCT00990782 is a NA study of Esophageal Lesion that has completed, run by The Cleveland Clinic. The registered enrollment target is 93 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00990782, a NA study of Esophageal Lesion, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 93 participants
- Enrollment target
- 1
- Study location
Study Summary
This study utilizes a disposable capsule endoscope (Pillcam ESO) to assess the condition of a patient's esophagus before and after the RFA procedure, as the injury rate to the esophagus has not been established.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST PillCam ESO Capsule Endoscope
Study Locations (1)
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2009-09 |
| Est. Completion | 2010-09 |
| Phase | NA |
What the finished NCT00990782 record still lists
NCT00990782 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 93 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Esophageal Lesion appearing as the primary indexed condition, and to 1 intervention - of which PillCam ESO Capsule Endoscope is the first listed.
NCT00990782 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT00990782 about?
NCT00990782 is a clinical study titled "Capsule Endoscopy for Post-Ablation Esophageal Lesion Assessment". This study utilizes a disposable capsule endoscope (Pillcam ESO) to assess the condition of a patient's esophagus before and after the RFA procedure, as the injury rate to the esophagus has not been established.
What is the current status of trial NCT00990782?
This trial is currently completed. It is a NA study. The enrollment target is 93 participants. The study started on 2009-09. Estimated completion is 2010-09.
What conditions does trial NCT00990782 study?
This clinical trial studies the following conditions: Esophageal Lesion.
What interventions are being tested in trial NCT00990782?
The interventions under investigation include: PillCam ESO Capsule Endoscope (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT00990782?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00990782 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Lesion
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00990782's enrollment target sits among peer trials
93 937th of 2000 higher than 1,064 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02203526 · 93 participants · Phase 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- NCT03089554 · 93 participants · Phase 2
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
- NCT05000021 · 93 participants · NA
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
- NCT05489887 · 93 participants · Phase 2
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia